News

November 16, 2017November 16, 2017

Inovio Starts Trial Testing Triple-combo Immunotherapy in Newly-diagnosed Glioblastoma

News

Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor may now enroll in a Phase 1b/2a clinical trial testing a triple immunotherapy combination for the cancer. Inovio Pharmaceuticals is leading the ... Read more

November 15, 2017November 15, 2017

Cancer Immunotherapy IMCgp100 Shows Early Positive Results in Advanced Uveal Melanoma

News

Immunocore presented data showing that its leading investigational immunotherapy, IMCgp100, leads to durable tumor responses and strong survival rates in patients with advanced uveal melanoma, following two Phase 1 clinical trials. ... Read more

November 14, 2017November 14, 2017

Early Results Suggest Opdivo Combo May Help People with Advanced Pancreatic Cancer

News

Adding cabiralizumab to Opdivo (nivolumab) induced durable clinical benefit in heavily treated pancreatic cancer patients, a group largely insensitive to immunotherapy, early results from an ongoing Phase 1a/1b trial show. ... Read more

November 13, 2017November 13, 2017

Boehringer Ingelheim, Sarah Cannon Research Institute to Study New Combo Therapy

News

Boehringer Ingelheim and Sarah Cannon Research Institute will jointly evaluate a SMAC mimetic candidate alone and in combination with an anti-PD-1 immunotherapy for the treatment of solid tumors. The two ... Read more

November 9, 2017November 9, 2017

FDA Lifts Clinical Hold on Cellectis’ UCART123 Phase 1 Trials in AML, BPDCN

News

The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on Cellectis‘ Phase 1 trials of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), allowing the ... Read more

November 8, 2017

FDA OKs Batu Biologics’ ValloVax for Clinical Investigation in Certain Solid Tumors

News

The U.S. Food and Drug Administration (FDA) has cleared Batu Biologics to advance its immunotherapy, ValloVax, into clinical trials for certain solid tumors, the company announced. This is the first immunotherapy targeting the blood ... Read more

November 7, 2017November 7, 2017

Super T-cells that Launch Dual Attack on Cancer Cells Enter Clinical Evaluation

News

Researchers at Roswell Park Cancer Institute in upstate New York have started a Phase 1/2a clinical trial to evaluate the use of “super T-cells” for the treatment of solid-tumor cancers. The trial ... Read more

November 6, 2017November 6, 2017

CBT Pharmaceuticals’ PD-L1 Antibody Shows Promising Anti-Tumor Activity in Preclinical Studies

News

CBT Pharmaceuticals‘ anti-PD-L1 antibody CBT-502 has shown promising immune activation and inhibition of tumor growth in preclinical models of cancer, according to new preclinical data. The data were presented in ... Read more

November 3, 2017November 3, 2017

UniQuest Partners with Merck Sharp & Dohme to Develop Immuno-Oncology Therapies in Australia

News

Merck Sharp & Dohme (MSD) has entered into a collaborative agreement with UniQuest, which specializes in commercializing the intellectual property of The University of Queensland, in Australia. The agreement aims ... Read more

November 2, 2017

Opdivo Moves a Step Closer to Being Expanded to Another Melanoma Patient Population

News

Regulators have taken a step toward expanding the European Union’s approval of Opvido (nivolumab) as a melanoma treatment to an additional group of patients. The step the European Medicines Agency took was accepting Bristol-Myers ... Read more